Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index; 57 of the 96 sources its claims cite were checked for support.

Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review

Open access

Abstract

INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and cognitive decline, primarily due to dysfunction of acetylcholine caused by acetylcholinesterase and butyrylcholinesterase. While synthetic cholinesterase inhibitors like donepezil, rivastigmine, and galantamine are commonly used, they have notable side effects, prompting interest in natural alternatives. Medicinal plants, rich in bioactive compounds like flavonoids and alkaloids, have shown potential as cholinesterase inhibitors with additional antioxidants and anti-inflammatory benefits. This study aimed to evaluate the cholinesterase-inhibiting effects of various plant species and their compounds to identify new therapeutic candidates and reduce side effects. METHOD: A PRISMA-compliant review was conducted, screening studies from multiple databases, with a final inclusion of 64 in vivo studies. RESULTS: , which improved memory, reduced oxidative stress, and provided neuroprotection. Some extracts also reduced amyloid plaques, enhanced neuronal integrity, and restored cholinesterase activity, indicating their potential as therapeutic agents for AD and other neurodegenerative diseases. CONCLUSIONS: The findings underscore the promise of plant-based compounds in treating cognitive decline and cholinergic dysfunction in AD, advocating for further research into their therapeutic potential.

Overview

CoChat Summary

TL;DR

This PRISMA-guided systematic review assessed whether plant species and their components inhibit cholinesterase activity in Alzheimer’s-related neuron and animal models. It included 64 in vivo studies and concluded that many plant extracts and compounds reduced AChE and/or BChE activity while also improving memory, oxidative stress, and other neuroprotective outcomes.

Key findings

  • The search yielded 1,571 records; after screening and eligibility assessment, 64 articles met inclusion criteria.
  • Included studies were all in vivo animal models of Alzheimer’s disease or Alzheimer’s-like impairment, with scopolamine the most common inducer (n = 39), followed by AlCl3 (n = 9), Aβ (n = 6), STZ (n = 4), TMT (n = 2), transgenic dementia models (n = 2), H2O2 (n = 1), and 3-NPA (n = 1).
  • Across the included studies, plant extracts and compounds frequently reduced AChE and/or BChE activity and improved cognition, including examples such as Ferula ammoniacum and Elaeagnus umbellata in scopolamine models, Canna indica and Centella asiatica in AlCl3 models, and Evolvulus alsinoides and Clitoria ternatea in STZ models.
  • The review states that many extracts also showed antioxidant, anti-inflammatory, reduced amyloid plaque, and enhanced neuronal integrity effects, suggesting multitarget potential beyond cholinesterase inhibition.

Methods

  • PRISMA-compliant systematic review with protocol registered in PROSPERO (CRD42025585536).
  • Searched Medline (OvidSP), Embase (OvidSP), Web of Science Core Collection, PubMed, and Scopus from 29 August to 1 September 2024.
  • Included original in vivo animal studies of Alzheimer’s disease or Alzheimer’s-like models assessing plant extracts or isolated compounds for direct effects on AChE and/or BChE; data were extracted by three independent reviewers and qualitatively synthesized.

Limitations

  • The paper states that only in vivo animal studies were included; it excludes humans, in silico studies, molecular docking, isolated-enzyme studies, and studies without control groups, which limits direct clinical inference.
  • The text makes evident that the evidence base is heterogeneous in models, species, plant materials, doses, and routes of administration, which likely limits comparability across studies (not stated explicitly as a limitation).
  • The paper does not report a formal risk-of-bias or meta-analysis in the provided text, so the synthesis appears qualitative only (not stated in the paper).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/brainsci15020215

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 The physiological structure of the brain and neurons in (A) healthy brain and (B) brain affected by Alzheimer’s disease (AD). The figure was created using BioRender (https://www.biorender.com/).
Figure 1 The physiological structure of the brain and neurons in (A) healthy brain and (B) brain affected by Alzheimer’s disease (AD). The figure was created using BioRender (https://www.biorender.com/).CC BY · PubMed Central
Figure 2 Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow chart displaying the study identification and selection process.
Figure 2 Preferred reporting items for systematic reviews and meta-analysis (PRISMA) flow chart displaying the study identification and selection process.CC BY · PubMed Central

Verification

Claims the paper makes

33 Valid · 2 Not valid · 20 Not checked · 9 Own results and interpretations

14 more claims · 1 with their cited sources checked

Create a free account to see all 64 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 40
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 8

Create a free account to see these claims.

Citations

Cites

Show all 14 references

Research works printed but not linked: 1

  1. Ibrahim, 2016, Anti-acetylcholinesterase, anti-inflammatory and anti-oxidant activities of Mentha longifolia for treating alzheimer disease, Der Pharm. Lett., 8, 34

Cited by

See all 35

Metadata

Authors
ALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M.
Affiliations
King Faisal University (SA)
Corresponding author
ALNasser, Maryam N.
Venue
Brain Sciences
Publisher
MDPI AG
Published
2025-02-19
Volume
15
Issue
2
Pages
215
ISSN
2076-3425 (ISSN-L)
OpenAlex
W4407740417
Cited by
35
References
14
Citations by year
2026: 25 · 2025: 10
FWCI
4.70
Type
journal article
Language
en
Open access
Locations
  • Brain Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
Deanship of Scientific Research, Vice Presidency for Graduate Studies and Scientific Research, King Faisal University, Saudi Arabia (KFU250395)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
  • Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
cholinesterase inhibitors, Alzheimer's disease, medicinal plants, acetylcholinesterase, butyrylcholinesterase, flavonoids, alkaloids, neuroprotection, oxidative stress, amyloid plaques, cognitive decline, cholinergic dysfunction, plant extracts

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review. https://app.cochat.ai/papers/10.3390/brainsci15020215
The paper
ALNasser, M. N., Alboraiy, G. M., Alsowig, E. M., & Alqattan, F. M. (2025). Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review. Brain Sciences. https://doi.org/10.3390/brainsci15020215

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.